Abstract: An endoluminal prosthesis is described and comprises a stent (40), At least one barb (42) secured to the stent, and a degradable barb guard (52) covering at least a portion of the barb and protecting the distal tip when the stent is in a compressed configuration. The barb guard (52) comprises a degradable structure that degrades to expose the distal tip of the barb when the stent is placed in a vessel.

Abstract: A coated medical device (10) including a structure (12) adapted for introduction into a passage or vessel of a patient. The structure is formed of preferably a non-porous base material (14) having a bioactive material layer (18) disposed thereon. The medical device is preferably an implantable stent or balloon (26) of which the bioactive material layer is deposited thereon. The stent can be positioned around the balloon and another layer of the bioactive material posited over the entire structure and extending beyond the ends of the positioned stent. The ends of the balloon extend beyond the ends of the stent and include the bioactive material thereon for delivering the bioactive material to the cells of a vessel wall coming in contact therewith. The balloon further includes a layer of hydrophilic material (58) positioned between the base and bioactive material layers of the balloon.

Abstract: A stent graft has a tubular side arm which can be angled proximally and distally and from side to side. The wall of the stent graft in the vicinity of the side arm has a loose fold of the graft material and the side arm is fastened to the loose fold of graft material. The tubular side arm has an inner end and an outer end and is fastened into the loose fold of graft material by a circumferential fastening around the tubular side arm between the inner end and the outer end so that the tubular side arm extends partially within the tubular body of the stent graft and partially outside the tubular body of the stent graft. The loose fold of graft material can be formed by the graft material defining a recess in the wall of the stent graft. To enable movement or angulation proximally and distally and from side to side the loose fold of graft material is provided both proximally and distally of the tubular side arm and circumferentially to each side of the tubular side arm.

Abstract: A self-expanding or otherwise expandable artificial valve prostheses for deployment within a body passageway, such as a vessel or duct of a patient. The valve prostheses include a support structure having an outer frame, a supporting member and a valve leaflet. The portion of the valve leaflet is supported by the supporting member and is positioned away from the wall of the body passageway when the device is deployed within the body passageway.

Abstract: An infusion mechanism for treating an intraluminal site in a patient includes an infusion catheter having an elongate body with a proximal body end defining at least one fluid supply orifice, and a distal body end. The elongate body defines a high head loss lumen in fluid communication with a first set of side ports defining a proximal infusion zone. The elongate body further defines a low head loss lumen in fluid communication with a second set of side ports defining a distal infusion zone.

Abstract: A coated implantable medical device includes a structure adapted for introduction into the vascular system, esophagus, trachea, colon, biliary tract, or urinary tract; at least one coating layer posited on one surface of the structure; and at least one layer of a bioactive material posited on at least a portion of the coating layer. Preferably the structure is a stent graft.

Abstract: An attachment system for attaching an intravascular device to a vessel wall of a body vessel is disclosed. The attachment system includes an intravascular device and biological attachment material connected to the intravascular device. The biological attachment material is configured to attach the intravascular device to the vessel wall.

Abstract: This disclosure relates to implantable medical devices coated with a taxane therapeutic agent, such as paclitaxel, in one or more solid form(s) having varying dissolution rates. Particularly preferred coatings comprise amorphous and/or solvated solid forms of taxane therapeutic agents that provide durable coatings that release the taxane over a desired period of time, which can be varied in the absence of a polymer by selecting the type and amount of solid forms of the taxane therapeutic agent in the coating. Other preferred embodiments relate to methods of coating medical devices and methods of treatment. The coatings can provide a sustained release of the taxane therapeutic agent within a body vessel without containing a polymer to achieve the desired rate of paclitaxel elution.

Abstract: An occlusion device includes a tubular expandable body with a frame that has a plurality of interconnected members configured to expand within a body vessel and to collapse for delivery or retrieval of the device. The occlusion device further includes a hydrophilic polyurethane hydrogel layer attached to the interconnected members of the tubular expandable body. The polyurethane hydrogel layer expands upon exposure to an aqueous environment.

Abstract: A stent graft (40) for treating Type-A dissections in the ascending aorta (22) is provided with a plurality of diameter reducing suture loops (56-60) operable to constrain the stent graft during deployment thereof in a patient's aorta. The diameter reducing loops (56-60) allow the stent graft (40) to be partially deployed, in such a manner that its location can be precisely adjusted in the patient's lumen. In this manner, the stent graft can be placed just by the coronary arteries (26, 28) with confidence that these will not be blocked. The stent graft (40) is also provided with proximal and distal bare stents (44,52) for anchoring purposes.

Abstract: Various stents and stent-graft systems for treatment of medical conditions are disclosed. In one embodiment, an exemplary stent-graft system may be used for endovascular treatment of a thoracic aortic aneurysm. The stent-graft system may comprise proximal and distal components, each comprising a graft having proximal and distal ends, where upon deployment the proximal and distal components at least partially overlap with one another to provide a fluid passageway therebetween. The proximal component may comprise a proximal stent having a plurality of proximal and distal apices connected by a plurality of generally straight portions, where a radius of curvature of at least one of the proximal apices may be greater than the radius of curvature of at least one of the distal apices. The distal component may comprise a proximal z-stent coupled to the graft, where the proximal end of the graft comprises at least scallop formed therein that generally follows the shape of the proximal z-stent.

Abstract: An attachment system for attaching an intravascular device to a vessel wall of a body vessel is disclosed. The attachment system has an intravascular device having a first end and a second end. The intravascular device defines a longitudinal axis along a length thereof. Several struts are connected to one or more ends of the intravascular device. Each strut is configured to move along a strut path relative to the longitudinal axis between an expanded state for engaging the vessel wall and a collapsed state for delivery or retrieval. Each strut has a free end configured to engage the vessel wall in the expanded state.

Abstract: An attachment system for attaching an intravascular device to a vessel wall of a body vessel is disclosed. The attachment system includes a tubular expandable body defining a lumen therethrough. The tubular expandable body is configured to move between an expanded state to contact the body vessel and a collapsed state for delivery or retrieval. The tubular expandable body is configured to contact the vessel wall along the length of the tubular expandable body in the expanded state when deployed in the body vessel. An intravascular device is held to the exterior side of the tubular expandable body and is configured to contact the vessel wall when the tubular expandable body is in the expanded state and the system is deployed within a body vessel.

Abstract: This disclosure relates to implantable medical devices coated with a taxane therapeutic agent, such as paclitaxel, in one or more solid form(s) having varying dissolution rates. Particularly preferred coatings comprise amorphous and/or solvated solid forms of taxane therapeutic agents that provide durable coatings that release the taxane over a desired period of time, which can be varied in the absence of a polymer by selecting the type and amount of solid forms of the taxane therapeutic agent in the coating. Other preferred embodiments relate to methods of coating medical devices and methods of treatment. The coatings can provide a sustained release of the taxane therapeutic agent within a body vessel without containing a polymer to achieve the desired rate of paclitaxel elution.

Abstract: A coated implantable medical device 10 includes a structure 12 adapted for introduction into the vascular system, esophagus, trachea, colon, biliary tract, or urinary tract, and at least one layer 18 of an immunosuppressive agent posited over at least one surface of the structure 12. Optionally, the device 10 can include at least one porous, preferably polymeric layer 20 posited over the layer 18 of immunosuppressive agent, and can alternatively or additionally include at least one coating layer 16 posited on one surface of the structure 12, the at least one layer 18 of immunosuppressive agent being posited in turn on at least a portion of the coating layer 16. The porous layer 20 and the coating layer 16 each provide for the controlled release of the bioactive material from the device 10. The structure 12 is preferably configured as a coronary stent. The polymer of the porous layer 20 is preferably applied by vapor or plasma deposition.

Abstract: A coated implantable medical device 10 includes a structure 12 adapted for introduction into the vascular system, esophagus, trachea, colon, biliary tract, or urinary tract; at least one coating layer 16 posited on one surface of the structure; and at least one layer 18 of a bioactive material posited on at least a portion of the coating layer 16, wherein the coating layer 16 provides for the controlled release of the bioactive material from the coating layer. In addition, at least one porous layer 20 can be posited over the bioactive material layer 18, wherein the porous layer includes a polymer and provides for the controlled release of the bioactive material therethrough. Preferably, the structure 12 is a coronary stent. The porous layer 20 includes a polymer applied preferably by vapor or plasma deposition and provides for a controlled release of the bioactive material.

Abstract: An endoluminal device comprises a stent and a tubular graft supported by the stent. The graft has a proximal and a distal opening and comprises a synthetic material and a bioremodelable material. The bioremodelable material is disposed on an exterior surface in at least one band adjacent at least one of the proximal and distal openings.

Abstract: This disclosure relates to endolumenal medical devices coated with a taxane therapeutic agent in one or more solid form(s) having varying dissolution rates. Particularly preferred coatings comprise amorphous paclitaxel, dihydrate paclitaxel, or combinations thereof that provide durable coatings that release paclitaxel over a desired period of time, which can be on the order of hours, days or weeks. Preferred embodiments relate to medical device coatings of paclitaxel, or paclitaxel analogs or derivatives, having one or more polymorph solid forms that provide a prolonged release of paclitaxel within a body vessel without requiring a polymer carrier or barrier layer to achieve the desired rate of paclitaxel elution.

Abstract: A medical device is provided. The device includes a cannula with a lumen defined therethrough and an upper portion, a right side portion, a bottom portion, and a left side portion each substantially equally spaced from their respective neighboring portion around the circumferential surface of the cannula. The cannula additionally includes a plurality of apertures disposed through the distal end portion to provide communication from the lumen and a visually perceptible indicator that is configured to allow the cannula to be positioned at an appropriate rotational position within the patient.

Abstract: A method for deploying a stent delivery system having a blowmolded holder is provided. The stent is configured to expand from a first diameter to a second diameter. The holder is blowmolded to an inner surface of the compressed state. The holder contacts the inner surface and at least portions of side surfaces of the stent, and the holder and the stent have an interference fit therebetween. The deployment method includes delivering the compressed stent placed on the blowmolded holder and the holder into a predetermined deployment side. The deployment method further includes releasing the stent from interference with the holder and expanding the stent from the compressed stent to the expanded stent.